Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

IDEAYA Biosciences (NASDAQ:IDYA) executives outlined multiple upcoming clinical catalysts at Citi’s 2026 Virtual Oncology ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 December 2024) The European Organisation for Research and Treatment of Cancer (EORTC), an independent clinical cancer research ...

Nathan L. Scott, M.D., discusses the risk of recurrence within diagnosed uveal melanoma patients. Uveal Melanoma Prognosis and Risk Stratification For patients diagnosed with uveal melanoma, what is ...

Completed Phase I DIONE-01 study demonstrates clinical activity and long-term safety of roginolisib, a unique allosteric modulator of PI3Kδ Patients with uveal melanoma showed a doubling of overall ...

Adding the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab to percutaneous hepatic perfusion may improve survival outcomes in patients with ...

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication ...

A form of T-cell therapy targeting a highly expressed antigen in uveal melanoma, a rare form of the disease, appears to be tolerable and efficacious, even though the tumors are considered to be ...

ROCHESTER, Minnesota — Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better ...